Corporate News
Result of AGM
09 June 2025
Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that at the AGM held earlier today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:
Resolution | For | Against |
01 | 572,589,782 | 33,404 |
02 | 522,618,153 | 49,986,337 |
03 | 572,211,914 | 85,763 |
04 | 532,209,384 | 38,679,812 |
05 | 533,474,486 | 38,667,157 |
06 | 525,097,507 | 38,679,812 |
07 | 570,603,589 | 899,739 |
08 | 570,264,453 | 1,959,346 |
Enquiries:
Polarean Imaging plc | ||||||
Christopher von Jako, Ph.D., Chief Executive Officer Charles Osborne, Chief Financial Officer | Via Walbrook PR
| |||||
| ||||||
Stifel (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||||
Nicholas Moore / Nick Harland / Brough Ransom / Ben Good | ||||||
| ||||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |||||
Anna Dunphy / Paul McManus / Marcus Ulker |
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
Latest News
-
Promotion & Sales Representative Agreement
24 June 2025 -
Result of AGM
09 June 2025 -
FDA expands XENOVIEW® indication to include children from six years of age
02 June 2025
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts